by Simon Goodley and Julia Kollewe on (#7006G)
Decision means none of drugmaker's much-trumpeted 650m UK investment package is currently proceedingThe drugmaker AstraZeneca has paused a planned 200m expansion of its Cambridge research site, completing a depressing week for the UK pharmaceutical industry.The decision by the UK's largest company means none of its much-trumpeted 650m investment package in the UK - which was originally announced in March 2024 - is proceeding. Continue reading...